Zydus' Nesher Pharma gets USFDA nod to market influenza drug

Published On 2017-10-30 06:37 GMT   |   Update On 2017-10-30 06:37 GMT

New Delhi: Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza.


"Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml", Zydus Cadila said in a statement.


The product is used in the treatment and prevention of influenza, it added.


The drug will be produced at Nesher Pharmaceuticals' manufacturing facility located at St Louis, US, Zydus Cadila said.


The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company's filing process.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News